Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-03-19

AUTHORS

John M. Magenau, Thomas Braun, Pavan Reddy, Brian Parkin, Attaphol Pawarode, Shin Mineishi, Sung Choi, John Levine, Yumeng Li, Gregory Yanik, Carrie Kitko, Tracey Churay, David Frame, Mary Mansour Riwes, Andrew Harris, Dale Bixby, Daniel R. Couriel, Steven C. Goldstein

ABSTRACT

The optimal intensity of conditioning for allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) remains undefined. Traditionally, myeloablative conditioning regimens improve disease control, but at the risk of greater nonrelapse mortality. Because fludarabine with myeloablative doses of intravenous busulfan using pharmacokinetic monitoring has excellent tolerability, we reasoned that this regimen would limit relapse without substantially elevating toxicity when compared to reduced intensity conditioning. We retrospectively analyzed 148 consecutive AML patients in remission receiving T cell replete HCT conditioned with fludarabine and intravenous busulfan at doses defined as reduced (6.4 mg/kg; FluBu2, n = 63) or myeloablative (12.8 mg/kg; FluBu4, n = 85). Early and late nonrelapse mortality (NRM) was similar among FluBu4 and FluBu2 recipients, respectively (day + 100: 4 vs 0 %; 5 years: 19 vs 22 %; p = 0.54). NRM did not differ between FluBu4 and FluBu2 in patients >50 years of age (24 vs 22 %, p = 0.75). Relapse was lower in recipients of FluBu4 (5 years: 30 vs 49 %; p = 0.04), especially in patients with poor risk cytogenetics (22 vs 59 %; p = 0.02) and those >50 years of age (28 vs 51 %; p = 0.02). Overall survival favored FluBu4 recipients at 5 years (53 vs 34 %, p = 0.02), a finding confirmed in multivariate analysis (HR: 0.57; 95 % CI: 0.34–0.95; p = 0.03). These data suggest that myeloablative FluBu4 may provide equivalent NRM, reduced relapse, and improved survival compared to FluBu2, emphasizing the importance of busulfan dose in conditioning for AML. More... »

PAGES

1033-1041

References to SciGraph publications

  • 2011-03-28. SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS in BONE MARROW TRANSPLANTATION
  • 2010-02-11. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up in LEUKEMIA
  • 2005-09-29. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) in LEUKEMIA
  • 2008-09-01. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center in BONE MARROW TRANSPLANTATION
  • 2005-11-24. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity in LEUKEMIA
  • 2014-06-30. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT in BONE MARROW TRANSPLANTATION
  • 2003-01-03. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience in LEUKEMIA
  • 2005-11-03. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis in LEUKEMIA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00277-015-2349-4

    DOI

    http://dx.doi.org/10.1007/s00277-015-2349-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1005008575

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/25784222


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Busulfan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy, Combination", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematopoietic Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myeloid, Acute", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myeloablative Agonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Remission Induction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation Conditioning", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation, Homologous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vidarabine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Blood and Marrow Transplant Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, F4860 University Hospital South, 48109-5932, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
                "Blood and Marrow Transplant Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, F4860 University Hospital South, 48109-5932, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Magenau", 
            "givenName": "John M.", 
            "id": "sg:person.01231243201.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231243201.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.214458.e", 
              "name": [
                "Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Braun", 
            "givenName": "Thomas", 
            "id": "sg:person.016431462577.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016431462577.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Reddy", 
            "givenName": "Pavan", 
            "id": "sg:person.01361646751.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361646751.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Parkin", 
            "givenName": "Brian", 
            "id": "sg:person.01206464504.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206464504.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pawarode", 
            "givenName": "Attaphol", 
            "id": "sg:person.01105607413.87", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105607413.87"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Alabama at Birmingham, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.265892.2", 
              "name": [
                "University of Alabama at Birmingham, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mineishi", 
            "givenName": "Shin", 
            "id": "sg:person.0605001434.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605001434.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Choi", 
            "givenName": "Sung", 
            "id": "sg:person.013567107537.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013567107537.52"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Levine", 
            "givenName": "John", 
            "id": "sg:person.016412243202.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016412243202.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.214458.e", 
              "name": [
                "Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Li", 
            "givenName": "Yumeng", 
            "id": "sg:person.0732161436.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732161436.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yanik", 
            "givenName": "Gregory", 
            "id": "sg:person.012664666607.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012664666607.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kitko", 
            "givenName": "Carrie", 
            "id": "sg:person.0652201227.93", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652201227.93"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Churay", 
            "givenName": "Tracey", 
            "id": "sg:person.01251644625.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251644625.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Frame", 
            "givenName": "David", 
            "id": "sg:person.01067776104.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067776104.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Riwes", 
            "givenName": "Mary Mansour", 
            "id": "sg:person.0606171014.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606171014.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Harris", 
            "givenName": "Andrew", 
            "id": "sg:person.013650256500.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013650256500.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bixby", 
            "givenName": "Dale", 
            "id": "sg:person.01171443031.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171443031.72"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Couriel", 
            "givenName": "Daniel R.", 
            "id": "sg:person.011456235437.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011456235437.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412590.b", 
              "name": [
                "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Goldstein", 
            "givenName": "Steven C.", 
            "id": "sg:person.016115210252.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.leu.2404037", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042454383", 
              "https://doi.org/10.1038/sj.leu.2404037"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2402761", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012794193", 
              "https://doi.org/10.1038/sj.leu.2402761"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2014.133", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005594815", 
              "https://doi.org/10.1038/bmt.2014.133"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2011.69", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052594326", 
              "https://doi.org/10.1038/bmt.2011.69"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2008.300", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018842765", 
              "https://doi.org/10.1038/bmt.2008.300"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2010.12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040639262", 
              "https://doi.org/10.1038/leu.2010.12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2404010", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007163730", 
              "https://doi.org/10.1038/sj.leu.2404010"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403967", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023301181", 
              "https://doi.org/10.1038/sj.leu.2403967"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2015-03-19", 
        "datePublishedReg": "2015-03-19", 
        "description": "The optimal intensity of conditioning for allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) remains undefined. Traditionally, myeloablative conditioning regimens improve disease control, but at the risk of greater nonrelapse mortality. Because fludarabine with myeloablative doses of intravenous busulfan using pharmacokinetic monitoring has excellent tolerability, we reasoned that this regimen would limit relapse without substantially elevating toxicity when compared to reduced intensity conditioning. We retrospectively analyzed 148 consecutive AML patients in remission receiving T cell replete HCT conditioned with fludarabine and intravenous busulfan at doses defined as reduced (6.4\u00a0mg/kg; FluBu2, n\u2009=\u200963) or myeloablative (12.8\u00a0mg/kg; FluBu4, n\u2009=\u200985). Early and late nonrelapse mortality (NRM) was similar among FluBu4 and FluBu2 recipients, respectively (day\u2009+\u2009100: 4 vs 0\u00a0%; 5\u00a0years: 19 vs 22\u00a0%; p\u2009=\u20090.54). NRM did not differ between FluBu4 and FluBu2 in patients >50\u00a0years of age (24 vs 22\u00a0%, p\u2009=\u20090.75). Relapse was lower in recipients of FluBu4 (5\u00a0years: 30 vs 49\u00a0%; p\u2009=\u20090.04), especially in patients with poor risk cytogenetics (22 vs 59\u00a0%; p\u2009=\u20090.02) and those >50\u00a0years of age (28 vs 51\u00a0%; p\u2009=\u20090.02). Overall survival favored FluBu4 recipients at 5\u00a0years (53 vs 34\u00a0%, p\u2009=\u20090.02), a finding confirmed in multivariate analysis (HR: 0.57; 95\u00a0% CI: 0.34\u20130.95; p\u2009=\u20090.03). These data suggest that myeloablative FluBu4 may provide equivalent NRM, reduced relapse, and improved survival compared to FluBu2, emphasizing the importance of busulfan dose in conditioning for AML.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00277-015-2349-4", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1358129", 
            "issn": [
              "0939-5555", 
              "1432-0584"
            ], 
            "name": "Annals of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "94"
          }
        ], 
        "keywords": [
          "hematopoietic stem cell transplantation", 
          "acute myeloid leukemia", 
          "nonrelapse mortality", 
          "years of age", 
          "intravenous busulfan", 
          "myeloid leukemia", 
          "cell-replete hematopoietic stem cell transplantation", 
          "allogeneic hematopoietic stem cell transplantation", 
          "greater nonrelapse mortality", 
          "late nonrelapse mortality", 
          "poor-risk cytogenetics", 
          "myeloablative conditioning regimens", 
          "consecutive AML patients", 
          "stem cell transplantation", 
          "risk cytogenetics", 
          "conditioning regimens", 
          "overall survival", 
          "improved survival", 
          "busulfan dose", 
          "allogeneic transplantation", 
          "AML patients", 
          "excellent tolerability", 
          "cell transplantation", 
          "myeloablative doses", 
          "intensity conditioning", 
          "pharmacokinetic monitoring", 
          "multivariate analysis", 
          "Disease Control", 
          "patients", 
          "recipients", 
          "remission", 
          "busulfan", 
          "relapse", 
          "transplantation", 
          "survival", 
          "leukemia", 
          "mortality", 
          "doses", 
          "optimal intensity", 
          "age", 
          "years", 
          "tolerability", 
          "regimens", 
          "regimen", 
          "fludarabine", 
          "dose", 
          "conditioning", 
          "risk", 
          "toxicity", 
          "cytogenetics", 
          "findings", 
          "control", 
          "monitoring", 
          "data", 
          "importance", 
          "analysis", 
          "intensity", 
          "replete HCT", 
          "FluBu4", 
          "FluBu2 recipients", 
          "FluBu2", 
          "recipients of FluBu4", 
          "FluBu4 recipients", 
          "myeloablative FluBu4", 
          "equivalent NRM", 
          "myeloablative FluBu4 conditioning", 
          "FluBu4 conditioning", 
          "reduced intensity FluBu2 conditioning", 
          "intensity FluBu2 conditioning", 
          "FluBu2 conditioning"
        ], 
        "name": "Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission", 
        "pagination": "1033-1041", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1005008575"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00277-015-2349-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "25784222"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00277-015-2349-4", 
          "https://app.dimensions.ai/details/publication/pub.1005008575"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:24", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_666.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00277-015-2349-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2349-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2349-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2349-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-015-2349-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    363 TRIPLES      22 PREDICATES      122 URIs      106 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00277-015-2349-4 schema:about N1351d00c5bde4032aa3c4bdbf7dec2ad
    2 N26cb429e212b4935b532a6e62f2260c0
    3 N2de7dfdda48a42eb9ebf16af6c70c42e
    4 N5549a21254c7421dac8beb936812d56f
    5 N5fb6e32fbc6e4acb950fd75fbf631681
    6 N663d7efea30e42b4b22b544ae2f5a8f6
    7 N6cf344c8d8574cbfa70092d43d3e0c6e
    8 N73a85bbf43674f668bd2dd38cd771dee
    9 N778931eb7cd5407a90e3c3b491d2dd42
    10 N796725b9095f4b0db936b8b71a593c5d
    11 N81d8fb35c5aa41568902763cc2d12aeb
    12 N88183b5099e74f68bb02b586840f8e63
    13 N95b9f9f5f50c4726a16ecc9468a7d43f
    14 Nabde766c4d904c77ab59bfbf1af7d0ec
    15 Ne6384e7c9f024eceaf99edbdc657613a
    16 Neaaf5efc3d3d4d30800e8d65373bc37e
    17 Nf43f56dbed714fca997b501cf1b04d13
    18 Nfa7e340409a94cc893b4aa47a1a1142f
    19 anzsrc-for:11
    20 anzsrc-for:1112
    21 schema:author N6814b75a681e473fb32c93904e3900d6
    22 schema:citation sg:pub.10.1038/bmt.2008.300
    23 sg:pub.10.1038/bmt.2011.69
    24 sg:pub.10.1038/bmt.2014.133
    25 sg:pub.10.1038/leu.2010.12
    26 sg:pub.10.1038/sj.leu.2402761
    27 sg:pub.10.1038/sj.leu.2403967
    28 sg:pub.10.1038/sj.leu.2404010
    29 sg:pub.10.1038/sj.leu.2404037
    30 schema:datePublished 2015-03-19
    31 schema:datePublishedReg 2015-03-19
    32 schema:description The optimal intensity of conditioning for allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) remains undefined. Traditionally, myeloablative conditioning regimens improve disease control, but at the risk of greater nonrelapse mortality. Because fludarabine with myeloablative doses of intravenous busulfan using pharmacokinetic monitoring has excellent tolerability, we reasoned that this regimen would limit relapse without substantially elevating toxicity when compared to reduced intensity conditioning. We retrospectively analyzed 148 consecutive AML patients in remission receiving T cell replete HCT conditioned with fludarabine and intravenous busulfan at doses defined as reduced (6.4 mg/kg; FluBu2, n = 63) or myeloablative (12.8 mg/kg; FluBu4, n = 85). Early and late nonrelapse mortality (NRM) was similar among FluBu4 and FluBu2 recipients, respectively (day + 100: 4 vs 0 %; 5 years: 19 vs 22 %; p = 0.54). NRM did not differ between FluBu4 and FluBu2 in patients >50 years of age (24 vs 22 %, p = 0.75). Relapse was lower in recipients of FluBu4 (5 years: 30 vs 49 %; p = 0.04), especially in patients with poor risk cytogenetics (22 vs 59 %; p = 0.02) and those >50 years of age (28 vs 51 %; p = 0.02). Overall survival favored FluBu4 recipients at 5 years (53 vs 34 %, p = 0.02), a finding confirmed in multivariate analysis (HR: 0.57; 95 % CI: 0.34–0.95; p = 0.03). These data suggest that myeloablative FluBu4 may provide equivalent NRM, reduced relapse, and improved survival compared to FluBu2, emphasizing the importance of busulfan dose in conditioning for AML.
    33 schema:genre article
    34 schema:inLanguage en
    35 schema:isAccessibleForFree false
    36 schema:isPartOf N7562018577e64f2e9adec72e6e1f1e6c
    37 Nd78ed7a659004eed9ee8734707f28d9a
    38 sg:journal.1358129
    39 schema:keywords AML patients
    40 Disease Control
    41 FluBu2
    42 FluBu2 conditioning
    43 FluBu2 recipients
    44 FluBu4
    45 FluBu4 conditioning
    46 FluBu4 recipients
    47 acute myeloid leukemia
    48 age
    49 allogeneic hematopoietic stem cell transplantation
    50 allogeneic transplantation
    51 analysis
    52 busulfan
    53 busulfan dose
    54 cell transplantation
    55 cell-replete hematopoietic stem cell transplantation
    56 conditioning
    57 conditioning regimens
    58 consecutive AML patients
    59 control
    60 cytogenetics
    61 data
    62 dose
    63 doses
    64 equivalent NRM
    65 excellent tolerability
    66 findings
    67 fludarabine
    68 greater nonrelapse mortality
    69 hematopoietic stem cell transplantation
    70 importance
    71 improved survival
    72 intensity
    73 intensity FluBu2 conditioning
    74 intensity conditioning
    75 intravenous busulfan
    76 late nonrelapse mortality
    77 leukemia
    78 monitoring
    79 mortality
    80 multivariate analysis
    81 myeloablative FluBu4
    82 myeloablative FluBu4 conditioning
    83 myeloablative conditioning regimens
    84 myeloablative doses
    85 myeloid leukemia
    86 nonrelapse mortality
    87 optimal intensity
    88 overall survival
    89 patients
    90 pharmacokinetic monitoring
    91 poor-risk cytogenetics
    92 recipients
    93 recipients of FluBu4
    94 reduced intensity FluBu2 conditioning
    95 regimen
    96 regimens
    97 relapse
    98 remission
    99 replete HCT
    100 risk
    101 risk cytogenetics
    102 stem cell transplantation
    103 survival
    104 tolerability
    105 toxicity
    106 transplantation
    107 years
    108 years of age
    109 schema:name Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission
    110 schema:pagination 1033-1041
    111 schema:productId N76c5d93babea432489adf03bf760dae3
    112 Nb2f74197cf4649e685a258600b845acf
    113 Nc0e909b226c847a39d5eb51276b26fe5
    114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005008575
    115 https://doi.org/10.1007/s00277-015-2349-4
    116 schema:sdDatePublished 2021-11-01T18:24
    117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    118 schema:sdPublisher N76a31bfd7faf40c5afb11d9bf70e441d
    119 schema:url https://doi.org/10.1007/s00277-015-2349-4
    120 sgo:license sg:explorer/license/
    121 sgo:sdDataset articles
    122 rdf:type schema:ScholarlyArticle
    123 N0d295d9d1d774262a226946eb805c601 rdf:first sg:person.01105607413.87
    124 rdf:rest N788aae78c0fe4cc9b5c3ff9bac7b0979
    125 N1351d00c5bde4032aa3c4bdbf7dec2ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Retrospective Studies
    127 rdf:type schema:DefinedTerm
    128 N1c52cc0e893e4609ade3a0460b807596 rdf:first sg:person.016115210252.03
    129 rdf:rest rdf:nil
    130 N26cb429e212b4935b532a6e62f2260c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Remission Induction
    132 rdf:type schema:DefinedTerm
    133 N29ae16eeeb67434dac6b04b63fd6900c rdf:first sg:person.01171443031.72
    134 rdf:rest Na228cb03d9104c3d8ed6619a54f776cf
    135 N2cc885287e6b4fa1901e48b9573d5858 rdf:first sg:person.016431462577.13
    136 rdf:rest Nb9b74d20d15941c8a4d83d2be48d576d
    137 N2de7dfdda48a42eb9ebf16af6c70c42e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Adult
    139 rdf:type schema:DefinedTerm
    140 N43cb3d09b6a84ae2aa7dfb416ed0deb9 rdf:first sg:person.016412243202.58
    141 rdf:rest N6765a311119142e3a8931302a2336722
    142 N500eb1112b064d23ae7d673578055d97 rdf:first sg:person.013650256500.11
    143 rdf:rest N29ae16eeeb67434dac6b04b63fd6900c
    144 N5549a21254c7421dac8beb936812d56f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Aged
    146 rdf:type schema:DefinedTerm
    147 N5fb6e32fbc6e4acb950fd75fbf631681 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Middle Aged
    149 rdf:type schema:DefinedTerm
    150 N663d7efea30e42b4b22b544ae2f5a8f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Male
    152 rdf:type schema:DefinedTerm
    153 N6765a311119142e3a8931302a2336722 rdf:first sg:person.0732161436.62
    154 rdf:rest Nbb0095bac06447b9a72a439735393ed6
    155 N6814b75a681e473fb32c93904e3900d6 rdf:first sg:person.01231243201.65
    156 rdf:rest N2cc885287e6b4fa1901e48b9573d5858
    157 N6b2749e9e50944808246933d091e03b2 rdf:first sg:person.01206464504.47
    158 rdf:rest N0d295d9d1d774262a226946eb805c601
    159 N6cf344c8d8574cbfa70092d43d3e0c6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Busulfan
    161 rdf:type schema:DefinedTerm
    162 N6d0d346dea0149d08fc1fa5c66d8a79b rdf:first sg:person.01067776104.05
    163 rdf:rest Nc1363cb006824a978f5c1702922114d8
    164 N73a85bbf43674f668bd2dd38cd771dee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Survival Rate
    166 rdf:type schema:DefinedTerm
    167 N7562018577e64f2e9adec72e6e1f1e6c schema:volumeNumber 94
    168 rdf:type schema:PublicationVolume
    169 N76a31bfd7faf40c5afb11d9bf70e441d schema:name Springer Nature - SN SciGraph project
    170 rdf:type schema:Organization
    171 N76c5d93babea432489adf03bf760dae3 schema:name pubmed_id
    172 schema:value 25784222
    173 rdf:type schema:PropertyValue
    174 N778931eb7cd5407a90e3c3b491d2dd42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Transplantation Conditioning
    176 rdf:type schema:DefinedTerm
    177 N788aae78c0fe4cc9b5c3ff9bac7b0979 rdf:first sg:person.0605001434.43
    178 rdf:rest Na3ffb86ab06c48dfa01789ef7594fae4
    179 N796725b9095f4b0db936b8b71a593c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Transplantation, Homologous
    181 rdf:type schema:DefinedTerm
    182 N81d8fb35c5aa41568902763cc2d12aeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Leukemia, Myeloid, Acute
    184 rdf:type schema:DefinedTerm
    185 N8241db05bc1645eabcfd7506b0ecedda rdf:first sg:person.01251644625.47
    186 rdf:rest N6d0d346dea0149d08fc1fa5c66d8a79b
    187 N88183b5099e74f68bb02b586840f8e63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Vidarabine
    189 rdf:type schema:DefinedTerm
    190 N95b9f9f5f50c4726a16ecc9468a7d43f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Myeloablative Agonists
    192 rdf:type schema:DefinedTerm
    193 Na228cb03d9104c3d8ed6619a54f776cf rdf:first sg:person.011456235437.27
    194 rdf:rest N1c52cc0e893e4609ade3a0460b807596
    195 Na3ffb86ab06c48dfa01789ef7594fae4 rdf:first sg:person.013567107537.52
    196 rdf:rest N43cb3d09b6a84ae2aa7dfb416ed0deb9
    197 Nabde766c4d904c77ab59bfbf1af7d0ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Female
    199 rdf:type schema:DefinedTerm
    200 Nb2f74197cf4649e685a258600b845acf schema:name dimensions_id
    201 schema:value pub.1005008575
    202 rdf:type schema:PropertyValue
    203 Nb59b3c96fd8d4d47b0e552b61005648b rdf:first sg:person.0652201227.93
    204 rdf:rest N8241db05bc1645eabcfd7506b0ecedda
    205 Nb9b74d20d15941c8a4d83d2be48d576d rdf:first sg:person.01361646751.46
    206 rdf:rest N6b2749e9e50944808246933d091e03b2
    207 Nbb0095bac06447b9a72a439735393ed6 rdf:first sg:person.012664666607.49
    208 rdf:rest Nb59b3c96fd8d4d47b0e552b61005648b
    209 Nc0e909b226c847a39d5eb51276b26fe5 schema:name doi
    210 schema:value 10.1007/s00277-015-2349-4
    211 rdf:type schema:PropertyValue
    212 Nc1363cb006824a978f5c1702922114d8 rdf:first sg:person.0606171014.36
    213 rdf:rest N500eb1112b064d23ae7d673578055d97
    214 Nd78ed7a659004eed9ee8734707f28d9a schema:issueNumber 6
    215 rdf:type schema:PublicationIssue
    216 Ne6384e7c9f024eceaf99edbdc657613a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Hematopoietic Stem Cell Transplantation
    218 rdf:type schema:DefinedTerm
    219 Neaaf5efc3d3d4d30800e8d65373bc37e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    220 schema:name Drug Therapy, Combination
    221 rdf:type schema:DefinedTerm
    222 Nf43f56dbed714fca997b501cf1b04d13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Young Adult
    224 rdf:type schema:DefinedTerm
    225 Nfa7e340409a94cc893b4aa47a1a1142f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Humans
    227 rdf:type schema:DefinedTerm
    228 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    229 schema:name Medical and Health Sciences
    230 rdf:type schema:DefinedTerm
    231 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    232 schema:name Oncology and Carcinogenesis
    233 rdf:type schema:DefinedTerm
    234 sg:journal.1358129 schema:issn 0939-5555
    235 1432-0584
    236 schema:name Annals of Hematology
    237 schema:publisher Springer Nature
    238 rdf:type schema:Periodical
    239 sg:person.01067776104.05 schema:affiliation grid-institutes:grid.412590.b
    240 schema:familyName Frame
    241 schema:givenName David
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067776104.05
    243 rdf:type schema:Person
    244 sg:person.01105607413.87 schema:affiliation grid-institutes:grid.412590.b
    245 schema:familyName Pawarode
    246 schema:givenName Attaphol
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105607413.87
    248 rdf:type schema:Person
    249 sg:person.011456235437.27 schema:affiliation grid-institutes:grid.412590.b
    250 schema:familyName Couriel
    251 schema:givenName Daniel R.
    252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011456235437.27
    253 rdf:type schema:Person
    254 sg:person.01171443031.72 schema:affiliation grid-institutes:grid.412590.b
    255 schema:familyName Bixby
    256 schema:givenName Dale
    257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171443031.72
    258 rdf:type schema:Person
    259 sg:person.01206464504.47 schema:affiliation grid-institutes:grid.412590.b
    260 schema:familyName Parkin
    261 schema:givenName Brian
    262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206464504.47
    263 rdf:type schema:Person
    264 sg:person.01231243201.65 schema:affiliation grid-institutes:grid.412590.b
    265 schema:familyName Magenau
    266 schema:givenName John M.
    267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231243201.65
    268 rdf:type schema:Person
    269 sg:person.01251644625.47 schema:affiliation grid-institutes:grid.412590.b
    270 schema:familyName Churay
    271 schema:givenName Tracey
    272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251644625.47
    273 rdf:type schema:Person
    274 sg:person.012664666607.49 schema:affiliation grid-institutes:grid.412590.b
    275 schema:familyName Yanik
    276 schema:givenName Gregory
    277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012664666607.49
    278 rdf:type schema:Person
    279 sg:person.013567107537.52 schema:affiliation grid-institutes:grid.412590.b
    280 schema:familyName Choi
    281 schema:givenName Sung
    282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013567107537.52
    283 rdf:type schema:Person
    284 sg:person.01361646751.46 schema:affiliation grid-institutes:grid.412590.b
    285 schema:familyName Reddy
    286 schema:givenName Pavan
    287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361646751.46
    288 rdf:type schema:Person
    289 sg:person.013650256500.11 schema:affiliation grid-institutes:grid.412590.b
    290 schema:familyName Harris
    291 schema:givenName Andrew
    292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013650256500.11
    293 rdf:type schema:Person
    294 sg:person.016115210252.03 schema:affiliation grid-institutes:grid.412590.b
    295 schema:familyName Goldstein
    296 schema:givenName Steven C.
    297 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03
    298 rdf:type schema:Person
    299 sg:person.016412243202.58 schema:affiliation grid-institutes:grid.412590.b
    300 schema:familyName Levine
    301 schema:givenName John
    302 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016412243202.58
    303 rdf:type schema:Person
    304 sg:person.016431462577.13 schema:affiliation grid-institutes:grid.214458.e
    305 schema:familyName Braun
    306 schema:givenName Thomas
    307 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016431462577.13
    308 rdf:type schema:Person
    309 sg:person.0605001434.43 schema:affiliation grid-institutes:grid.265892.2
    310 schema:familyName Mineishi
    311 schema:givenName Shin
    312 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605001434.43
    313 rdf:type schema:Person
    314 sg:person.0606171014.36 schema:affiliation grid-institutes:grid.412590.b
    315 schema:familyName Riwes
    316 schema:givenName Mary Mansour
    317 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606171014.36
    318 rdf:type schema:Person
    319 sg:person.0652201227.93 schema:affiliation grid-institutes:grid.412590.b
    320 schema:familyName Kitko
    321 schema:givenName Carrie
    322 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652201227.93
    323 rdf:type schema:Person
    324 sg:person.0732161436.62 schema:affiliation grid-institutes:grid.214458.e
    325 schema:familyName Li
    326 schema:givenName Yumeng
    327 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732161436.62
    328 rdf:type schema:Person
    329 sg:pub.10.1038/bmt.2008.300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018842765
    330 https://doi.org/10.1038/bmt.2008.300
    331 rdf:type schema:CreativeWork
    332 sg:pub.10.1038/bmt.2011.69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052594326
    333 https://doi.org/10.1038/bmt.2011.69
    334 rdf:type schema:CreativeWork
    335 sg:pub.10.1038/bmt.2014.133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005594815
    336 https://doi.org/10.1038/bmt.2014.133
    337 rdf:type schema:CreativeWork
    338 sg:pub.10.1038/leu.2010.12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040639262
    339 https://doi.org/10.1038/leu.2010.12
    340 rdf:type schema:CreativeWork
    341 sg:pub.10.1038/sj.leu.2402761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012794193
    342 https://doi.org/10.1038/sj.leu.2402761
    343 rdf:type schema:CreativeWork
    344 sg:pub.10.1038/sj.leu.2403967 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023301181
    345 https://doi.org/10.1038/sj.leu.2403967
    346 rdf:type schema:CreativeWork
    347 sg:pub.10.1038/sj.leu.2404010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007163730
    348 https://doi.org/10.1038/sj.leu.2404010
    349 rdf:type schema:CreativeWork
    350 sg:pub.10.1038/sj.leu.2404037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042454383
    351 https://doi.org/10.1038/sj.leu.2404037
    352 rdf:type schema:CreativeWork
    353 grid-institutes:grid.214458.e schema:alternateName Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
    354 schema:name Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
    355 rdf:type schema:Organization
    356 grid-institutes:grid.265892.2 schema:alternateName University of Alabama at Birmingham, Birmingham, AL, USA
    357 schema:name University of Alabama at Birmingham, Birmingham, AL, USA
    358 rdf:type schema:Organization
    359 grid-institutes:grid.412590.b schema:alternateName Blood and Marrow Transplant Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, F4860 University Hospital South, 48109-5932, Ann Arbor, MI, USA
    360 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    361 schema:name Blood and Marrow Transplant Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, F4860 University Hospital South, 48109-5932, Ann Arbor, MI, USA
    362 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    363 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...